title: Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review.
abstract: BACKGROUND
  Brentuximab vedotin (BV) is an antibody-drug conjucate (ADC) comprising a CD30-directed antibody, conjugated to the microtubule-disrupting agent MMAE via a protease cleavable linker. BV is FDA approved for use in relapsed classical Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL). There are multiple publications for its utility in other malignancies such as diffuse large B-cell lymphoma (DLBCL), mycosis fungoides (MF), Sézary syndrome (SS), T-cell lymphomas (TCL), primary mediastinal lymphoma (PMBL), and post-transplant lymphoproliferative disorders (PTLD). We believe that BV could potentially provide a strong additional treatment option for patients suffering from NHL.
  
  
  OBJECTIVE
  Perform a systematic review on the use of BV in non-Hodgkin lymphoma (NHL) and other CD30+malignancies in humans.
  
  
  METHODS
  We searched various databases including PubMed (1946-2015), EMBASE (1947-2015), and Cochrane Central Register of Controlled Trials (1898-2015).
  
  
  METHODS
  Inclusion criteria specified all studies and case reports of NHLs in which BV therapy was administered.
  
  
  METHODS
  A total of 28 articles met these criteria and are summarized in this manuscript.
  
  
  CONCLUSIONS
  Our findings indicate that BV induces a variety of responses, largely positive in nature and variable between NHL subtypes. With additional, properly powered prospective studies, BV may prove to be a strong candidate in the treatment of various CD30+malignancies.
authors.affiliation: College of Pharmacy, University of Arizona, Tucson, AZ, 85721, United States.
authors.forename: Garrett K
authors.initials: GK
authors.lastname: Berger
authors.affiliation: College of Pharmacy, University of Arizona, Tucson, AZ, 85721, United States.
authors.forename: Ali
authors.initials: A
authors.lastname: McBride
authors.affiliation: College of Pharmacy, University of Arizona, Tucson, AZ, 85721, United States.
authors.forename: Stephanie
authors.initials: S
authors.lastname: Lawson
authors.affiliation: College of Pharmacy, University of Arizona, Tucson, AZ, 85721, United States.
authors.forename: Kelsey
authors.initials: K
authors.lastname: Royball
authors.affiliation: Departments of Medicine, University of Arizona, Tucson, AZ, 85721, United States.
authors.forename: Seongseok
authors.initials: S
authors.lastname: Yun
authors.affiliation: College of Medicine, University of Arizona, Tucson, AZ, 85721, United States.
authors.forename: Kevin
authors.initials: K
authors.lastname: Gee
authors.affiliation: Departments of Medicine, University of Arizona, Tucson, AZ, 85721, United States.
authors.forename: Irbaz
authors.initials: I
authors.lastname: Bin Riaz
authors.affiliation: University of Arizona Health Sciences Library, University of Arizona, Tucson, AZ 85721, United States.
authors.forename: Ahlam A
authors.initials: AA
authors.lastname: Saleh
authors.affiliation: Departments of Medicine, University of Arizona, Tucson, AZ, 85721, United States.
authors.forename: Soham
authors.initials: S
authors.lastname: Puvvada
authors.affiliation: Hematology, Oncology, Blood & Marrow Transplantation, Department of Medicine, University of Arizona, Tucson, AZ, 85721, United States. Electronic address: anwerf@email.arizona.edu.
authors.forename: Faiz
authors.initials: F
authors.lastname: Anwer
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D000079963:Brentuximab Vedotin; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D011446:Prospective Studies
chemical_list: D000970:Antineoplastic Agents; D018796:Immunoconjugates; D000079963:Brentuximab Vedotin
keywords: Brentuximab vedotin; CD30; Relapse or refractory NHL